LGTmedical has leveraged the synergies of award-winning interdisciplinary research, global foundations, and business expertise to establish the innovative core technologies, infrastructure, and partnerships and become a leading mHealth company. LGTmedical is focused on product and channel development to achieve the most scalable and clinically impactful mobile health solutions. The company is ISO 13485:2003 certified.

LGTmedical was founded in March 2012 and has offices in Vancouver and Victoria, British Columbia.  The company’s initial product, the Phone Oximeter™, is commercially known as Kenek O2.

The company’s goal is to meet the enormous global need for accurate, accessible and, most importantly, affordable medical diagnostics and vital signs monitoring. The company’s aim is to have significant impact on reducing global health inequities and will accomplish this through innovative technological advancements in mHealth and an innovative business approach blending societal and financial values to create a sustainable and profitable Socially Driven Business.  

At a Glance

Members 0
Partners 1

Organization Type

  • Social Impact
  • Social Enterprise
  • Corporation


V3-318 CSB, 950 West 28th Ave.
Vancouver, BC V5Z 4H4

T : 1-866-944-8607
E : contact@lgtmedical.com

Area of Focus

Mobile Health faces significant challenges producing meaningful, low-cost, cross-platform solutions for important global healthcare markets. LGTmedical has solved these challenges for diagnostic quality vital signs monitors. Through the development of a novel and universal audio-based interface called Kenek Core™, standard medical sensors can now be connected to mobile devices to provide low-cost, mobile vital signs monitoring. The Kenek Core technology utilizes the audio jack common to virtually all smartphones, cellphones, laptops, PCs and tablets to provide a universal access port for almost any type of medical sensor.  With this proprietary technology, in partnership with researchers at the University of British Columbia, the company will access developing world markets where the diagnostic impact is significant and critical, as well as multi-billion dollar high-income consumer and chronic care markets to achieve significant social and economic impact.